Grifols S.A.
ISIN: ES0171996087 | Ticker: GRF | LEI: 959800HSSNXWRKBK4N60
Country: Spain
Grifols, with presence in more than 100 countries, is a global pharmaceutical company specializing in the Hemotherapy sector, the medical discipline that treats disease using blood components.
Year founded1940
Served areaWorldwide
Headcount23,000
HeadquartersCl Jesus y Maria 6, 8022 Barcelona – Spain
| Line item in (eur) | 01.01.2019 | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|---|
| Assets | N/A | N/A | 15,274,776,000.00 | 19,233,835,000.00 | 21,533,977,000.00 |
| Noncurrent Assets | N/A | N/A | 12,109,822,000.00 | 13,723,555,000.00 | 16,880,390,000.00 |
| Property Plant And Equipment | N/A | N/A | 2,324,107,000.00 | 2,547,497,000.00 | 3,270,937,000.00 |
| Goodwill | N/A | N/A | 5,332,271,000.00 | 6,228,901,000.00 | 7,011,909,000.00 |
| Intangible Assets Other Than Goodwill | N/A | N/A | 1,557,650,000.00 | 1,636,950,000.00 | 2,949,147,000.00 |
| Investment Accounted For Using Equity Method | N/A | N/A | 1,869,020,000.00 | 1,999,776,000.00 | 1,955,177,000.00 |
| Deferred Tax Assets | N/A | N/A | 149,921,000.00 | 152,507,000.00 | 174,923,000.00 |
| Noncurrent Financial Assets At Amortised Cost | N/A | N/A | 195,149,000.00 | 358,161,000.00 | 582,175,000.00 |
| Current Assets | N/A | N/A | 3,164,954,000.00 | 5,510,280,000.00 | 4,653,587,000.00 |
| Inventories | N/A | N/A | 2,002,281,000.00 | 2,259,354,000.00 | 3,201,357,000.00 |
| Trade And Other Current Receivables | N/A | N/A | 520,158,000.00 | 499,708,000.00 | 738,651,000.00 |
| Current Trade Receivables | N/A | N/A | 383,233,000.00 | 432,197,000.00 | 608,688,000.00 |
| Other Current Receivables | N/A | N/A | 72,360,000.00 | 55,063,000.00 | 73,181,000.00 |
| Current Tax Assets Current | N/A | N/A | 64,565,000.00 | 12,448,000.00 | 56,782,000.00 |
| Current Financial Assets At Amortised Cost | N/A | N/A | 11,118,000.00 | 2,026,469,000.00 | 31,034,000.00 |
| Cash and cash equivalents | 1,033,792,000.00 | 741,982,000.00 | 579,647,000.00 | 2,675,611,000.00 | 547,979,000.00 |
| Noncurrent Assets Or Disposal Groups Classified As Held For Sale Or As Held For Distribution To Owners | N/A | N/A | N/A | 0.00 | 4,969,000.00 |
| Other Current Assets | N/A | N/A | 51,750,000.00 | 64,079,000.00 | 81,814,000.00 |
| Equity And Liabilities | N/A | N/A | 15,274,776,000.00 | 19,233,835,000.00 | 21,533,977,000.00 |
| Equity | 4,696,604,000.00 | 6,845,768,000.00 | 6,720,055,000.00 | 7,317,098,000.00 | 8,457,544,000.00 |
| Issued Capital | N/A | N/A | 119,604,000.00 | 119,604,000.00 | 119,604,000.00 |
| Share Premium | N/A | N/A | 910,728,000.00 | 910,728,000.00 | 910,728,000.00 |
| Treasury Shares | N/A | N/A | 43,734,000.00 | 164,189,000.00 | 162,220,000.00 |
| Equity Attributable To Owners Of Parent | N/A | N/A | 5,108,392,000.00 | 5,523,609,000.00 | 6,129,938,000.00 |
| Noncontrolling Interests | N/A | N/A | 1,611,663,000.00 | 1,793,489,000.00 | 2,327,606,000.00 |
| Liabilities | N/A | N/A | 8,554,721,000.00 | 11,916,737,000.00 | 13,076,433,000.00 |
| Noncurrent Liabilities | N/A | N/A | 7,219,583,000.00 | 8,442,425,000.00 | 11,120,586,000.00 |
| Noncurrent Provisions | N/A | N/A | 27,271,000.00 | 24,122,000.00 | 110,063,000.00 |
| Noncurrent Government Grants | N/A | N/A | 17,008,000.00 | 15,036,000.00 | 15,123,000.00 |
| Deferred Tax Liabilities | N/A | N/A | 556,813,000.00 | 633,984,000.00 | 1,034,823,000.00 |
| Other Noncurrent Liabilities | N/A | N/A | 16,391,000.00 | 333,000.00 | 15,000.00 |
| Current Liabilities | N/A | N/A | 1,335,138,000.00 | 3,474,312,000.00 | 1,955,847,000.00 |
| Current Provisions | N/A | N/A | 11,175,000.00 | 31,407,000.00 | 56,339,000.00 |
| Trade And Other Current Payables | N/A | N/A | 746,189,000.00 | 785,342,000.00 | 862,335,000.00 |
| Trade And Other Current Payables To Trade Suppliers | N/A | N/A | 601,618,000.00 | 628,992,000.00 | 731,918,000.00 |
| Other Current Payables | N/A | N/A | 141,089,000.00 | 151,834,000.00 | 114,730,000.00 |
| Current Tax Liabilities Current | N/A | N/A | 3,482,000.00 | 4,516,000.00 | 15,687,000.00 |
| Other Current Liabilities | N/A | N/A | 153,162,000.00 | 219,272,000.00 | 241,487,000.00 |
| Line item in (eur) | 01.01.2019/ 01.01.2020 |
01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|---|
| Revenue | 5,098,691,000.00 | 5,340,038,000.00 | 4,933,118,000.00 | 6,063,967,000.00 |
| Other Income | 0.00 | 0.00 | 16,302,000.00 | 22,235,000.00 |
| Profit Loss From Operating Activities | 1,131,365,000.00 | 996,132,000.00 | 595,064,000.00 | 805,680,000.00 |
| Finance Income | 114,197,000.00 | 8,021,000.00 | 11,551,000.00 | 33,859,000.00 |
| Finance Costs | 342,965,000.00 | 249,639,000.00 | 277,994,000.00 | 496,524,000.00 |
| Profit Loss Before Tax | 817,103,000.00 | 878,629,000.00 | 350,453,000.00 | 361,257,000.00 |
| Income Tax Expense Continuing Operations | 168,459,000.00 | 169,639,000.00 | 85,126,000.00 | 90,111,000.00 |
| Profit Loss From Continuing Operations | 648,644,000.00 | 708,990,000.00 | 265,327,000.00 | 271,146,000.00 |
| Profit (loss) | 648,644,000.00 | 708,990,000.00 | 265,327,000.00 | 271,146,000.00 |
| Profit Loss Attributable To Owners Of Parent | 625,146,000.00 | 618,546,000.00 | 188,726,000.00 | 208,279,000.00 |
| Profit Loss Attributable To Noncontrolling Interests | 23,498,000.00 | 90,444,000.00 | 76,601,000.00 | 62,867,000.00 |
| Line item in (eur) | 01.01.2019 | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|---|
| Profit (loss) | N/A | 648,644,000.00 | 708,990,000.00 | 265,327,000.00 | 271,146,000.00 |
| Adjustments For Reconcile Profit Loss | N/A | 569,960,000.00 | 409,766,000.00 | 574,493,000.00 | 780,436,000.00 |
| Adjustments For Decrease Increase In Inventories | N/A | 323,748,000.00 | -164,631,000.00 | 157,474,000.00 | 600,245,000.00 |
| Adjustments For Depreciation And Amortisation Expense | N/A | 302,455,000.00 | 321,533,000.00 | 359,767,000.00 | 407,864,000.00 |
| Other Adjustments For Noncash Items | N/A | 605,000.00 | 16,427,000.00 | -25,398,000.00 | -22,270,000.00 |
| Other Adjustments To Reconcile Profit Loss | N/A | 267,505,000.00 | 88,233,000.00 | 214,726,000.00 | 372,572,000.00 |
| Adjustments For Reconcile Profit Loss | N/A | 569,960,000.00 | 409,766,000.00 | 574,493,000.00 | 780,436,000.00 |
| Interest Paid Classified As Operating Activities | N/A | 236,179,000.00 | 155,788,000.00 | 155,120,000.00 | 350,387,000.00 |
| Interest Received Classified As Operating Activities | N/A | 9,487,000.00 | 3,773,000.00 | 407,000.00 | 4,054,000.00 |
| Income Taxes Paid Refund Classified As Operating Activities | N/A | 107,797,000.00 | 131,510,000.00 | 30,595,000.00 | 196,436,000.00 |
| Other Inflows Outflows Of Cash Classified As Operating Activities | N/A | -336,593,000.00 | -284,342,000.00 | -187,063,000.00 | -543,341,000.00 |
| Cash Flows From Used In Operating Activities | N/A | 568,933,000.00 | 1,110,336,000.00 | 596,975,000.00 | -10,867,000.00 |
| Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities | N/A | 2,708,000.00 | 272,000.00 | 639,000.00 | 3,284,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 310,383,000.00 | 280,154,000.00 | 247,373,000.00 | 266,491,000.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | N/A | 101,922,000.00 | 82,406,000.00 | 67,715,000.00 | 109,069,000.00 |
| Cash Flows From Used In Investing Activities | N/A | -548,789,000.00 | -858,115,000.00 | -854,149,000.00 | -1,978,823,000.00 |
| Payments To Acquire Or Redeem Entitys Shares | N/A | 0.00 | 0.00 | 125,703,000.00 | 3,459,000.00 |
| Proceeds From Borrowings Classified As Financing Activities | N/A | 120,079,000.00 | 108,541,000.00 | 3,324,399,000.00 | 1,134,168,000.00 |
| Repayments Of Borrowings Classified As Financing Activities | N/A | 53,809,000.00 | 272,877,000.00 | 495,327,000.00 | 1,207,253,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 73,785,000.00 | 79,037,000.00 | 82,692,000.00 | 104,287,000.00 |
| Dividends Paid Classified As Financing Activities | N/A | 238,740,000.00 | 113,230,000.00 | 258,946,000.00 | 592,000.00 |
| Other Inflows Outflows Of Cash Classified As Financing Activities | N/A | -90,552,000.00 | -7,953,000.00 | -75,500,000.00 | -2,787,000.00 |
| Cash Flows From Used In Financing Activities | N/A | -332,356,000.00 | -354,401,000.00 | 2,297,679,000.00 | -173,493,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | 20,402,000.00 | -60,155,000.00 | 55,459,000.00 | 35,551,000.00 |
| Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | N/A | -291,810,000.00 | -162,335,000.00 | 2,095,964,000.00 | -2,127,632,000.00 |
| Cash and cash equivalents | 1,033,792,000.00 | 741,982,000.00 | 579,647,000.00 | 2,675,611,000.00 | 547,979,000.00 |
Please note that some sums might not add up.
ES0171996087
LEI959800HSSNXWRKBK4N60
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryIBEX35
Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.